Telix Partners with EDAP, Profound for Prostate Cancer Imaging

Telix Pharmaceuticals announced collaborations with EDAP TMS S.A. and Profound Medical Corp. to integrate its PSMA-PET imaging agents, Gozellix® and Illuccix®, with advanced minimally invasive and image-guided ablative technologies for prostate cancer. These partnerships aim to enhance patient selection, treatment planning, and post-treatment monitoring, accelerating the adoption of novel therapeutic workflows. The focus is on generating clinical evidence to establish best practices and improve patient outcomes by preserving healthy tissue and minimizing side effects.